Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00103831 |
Recruitment Status :
Completed
First Posted : February 16, 2005
Last Update Posted : March 2, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer | Drug: Oral Taxane | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Official Title: | Phase I Alimta Combination With BMS-275183 (Oral Taxane) |
Actual Primary Completion Date : | May 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced or metastatic pretreated NSCLC
- Measurable disease
- Adequate hematologic, hepatic and renal functions.
- ECOG Performance Status 0-2
Exclusion Criteria:
- Inability to swallow capsules
- Recent significant cardiovascular disease
- Women who are pregnant or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00103831
United States, Colorado | |
Local Institution | |
Denver, Colorado, United States | |
United States, Minnesota | |
Local Institution | |
Rochester, Minnesota, United States | |
Canada, Ontario | |
Local Institution | |
Toronto, Ontario, Canada |
ClinicalTrials.gov Identifier: | NCT00103831 |
Other Study ID Numbers: |
CA165-021 |
First Posted: | February 16, 2005 Key Record Dates |
Last Update Posted: | March 2, 2010 |
Last Verified: | August 2008 |
NSCLC - non-small cell lung cancer |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Taxane Antineoplastic Agents |